{"0": ["Serotonin Receptor Modulation in SSRI Treatment", 2], "1": ["Aquatic Ecotoxicology", 0], "2": ["Risks of Prenatal Exposure", 1], "3": ["Quantification of SSRIs in Biological Samples", 2], "4": ["SSRIs for Obsessive-Compulsive Disorder (OCD)", 1], "5": ["SSRIs and the Cytochrome P450 System", 2], "6": ["Impact of SSRIs on Neurogenesis", 2], "7": ["The Chronic Unpredictable Mild Stress Model of Depression", 1], "8": ["Fluvoxamine for Depression", 1], "9": ["Pediatric Depression", 1], "10": ["SSRIs Effect on Neural Processing of Emotional Cues", 1], "11": ["Paroxetine Binding", 2], "12": ["Risk of Perinatal Exposure (Rodents)", 1], "13": ["SSRIs in Forced Swimming Test", 2], "14": ["SSRIs for PTSD", 2], "15": ["Sexual Dysfunction", 1], "16": ["Serotonin Syndrome", 1], "17": ["Sequenced Depression Treatment", 1], "18": ["Serotonin Transporter Gene and Antidepressant Response", 1], "19": ["Post-Stroke SSRI Use", 1], "20": ["Bleeding Risk", 1], "21": ["SSRI Utilization Patterns", 1], "22": ["SSRIs for Bipolar Depression", 1], "23": ["SSRIs in Dementias", 1], "24": ["Escitalopram for Depression", 1], "25": ["SSRIs for Pain", 1], "26": ["SSRIs Effect on Fear", 2], "27": ["Suicice Risk", 1], "28": ["Structural Basis of Serotonin Transporter Inhibition by SSRIs", 2], "29": ["SSRIs for Weight Management", 1], "30": ["Pharmacoeconomics of SSRIs for Depression", 0], "31": ["SSRIs for Panic Disorder", 1], "32": ["Paroxetine", 9], "33": ["Antidepressant-like Effects of Herbal Extracts in Animal Models", 2], "34": [" Depression in Patients with Cardiovascular Disease", 1], "35": ["SSRIs for (Psycho)dermatological Diseases", 1], "36": ["SSRIs and Inflammation", 1], "37": ["SSRIs for Generalized Anxiety Disorder (GAD)", 1], "38": ["Fracture Risk", 1], "39": ["Fluoxetine", 9], "40": ["SSRIs Effect on Sleep", 1], "41": ["Fluvoxamine for Covid 19", 1], "42": ["Pharmacological Treatment Strategies of Depression", 1], "43": ["QTC Prolongation", 1], "44": ["Oncopreventive and Oncolytic Properties of SSRIs", 1], "45": ["Premature Ejaculation", 1], "46": ["Extrapyramidal Reactions Risk", 1], "47": ["SSRIs for Depression in Diabetes Patients", 1], "48": ["SSRIs for Premenstrual Dysphoric Disorder (PMDD)", 1], "49": ["SSRIs for Depression with Cognitive Impairment", 1], "50": ["SSRIs for Eating Disorders", 1], "51": ["SSRIs for Alcohol Dependence", 1], "52": ["SSRIs for Irritable Bowel Syndrome", 1], "53": ["Menopausal Vasomotor Symptoms (Hot flashes)", 1], "54": ["SSRIs for Borderline Personality Disorder", 1], "55": ["SSRIs Effects on Neuroendocrine System", 2], "56": ["(Sertraline) Drug Delivery", 2], "57": ["SSRI Synthesis", 2], "58": ["SSRIs for Autism Spectrum Disorders", 1], "59": ["SSRIs for Depression in in Epileptic Patients", 1], "60": ["SSRIs for Substance Abuse (Cocaine)", 2], "61": ["SSRIs for Depression in Parkinsons Patients", 1], "62": ["SSRIs (Fluvoxamine) for Schizophrenia", 1], "63": ["SSRIs for Social Anxiety Disorder", 1], "64": ["SSRIs Effects on Ion Channels", 2], "65": ["Harmful Drug Interactions", 1], "66": ["Methylenedioxymethamphetamine (MDMA) Induced Neurotoxicity", 2], "67": ["Hyponatremia Risk", 1], "68": ["Sertraline for Depression", 9], "69": ["SSRIs Effect on Pulmonary Hypertension", 2], "70": ["SSRIs for Body Dysmorphic Disorder (BDD)", 1], "71": ["Forensic Drug Concentration", 1], "72": ["SSRIs for Pediatric Anxiety", 1], "73": ["SSRIs Effects on Antimicrobials and Gut Microbiome", 2], "74": ["Geriatric Depression", 1], "75": ["SSRI Safety Reviews", 1], "76": ["Citalopram for Depression", 9], "77": ["Agomelatin for Depression", 1], "78": ["Withdrawal Symptoms", 1], "79": ["Astrocyte Receptors as a Target for SSRIs", 2], "80": ["Genotype Mediated Response to SSRIs", 1], "81": ["Environmental Degradation of Antidepressants", 0], "82": ["Hepatotoxic Risk", 2], "83": ["SSRIs and Augmentation for Treatment Resistant Depression", 1], "84": ["Depression Treatment in Hepatitis Patients", 1], "85": ["SSRIs for Depression after Traumatic Brain Injury", 1], "86": ["Repeated SSRIs Exposures Effects on Dopamine Receptors", 2], "87": ["Hyperprolactinemia-related Symptoms", 1], "88": ["SSRI Use", 9], "89": ["SSRIs for Fibromyalgia", 1], "90": ["Sex differences in SSRI Response", 1], "91": ["SSRIs Effect on Male Fertility", 2], "92": ["SRRIs and Ocular Safety", 1], "93": ["SSRIs for Depression in Cancer", 1], "94": ["Gatways to Clinical Trials", 9], "95": ["Transcranial Direct Current Stimulation (tDCS) for Depression", 1], "96": ["Sertraline", 9], "97": ["Canine Behavioral Disorders", 0], "98": ["SSRIs in Model Organisms ( C. Elegans and Drosophilia)", 2], "99": ["Risk for Orofacial Pain Disorders", 1], "100": ["SSRIs for Enuresis", 1], "101": ["SSRIs for Migraine", 1], "102": ["SSRIs for Postpartum Depression", 1], "103": ["St. John's Wort for Depression", 1], "104": ["SSRIs for Behavioral Addictions", 1], "105": ["SSRIs for Depression in Kidney Disease Patients", 1], "106": ["Predicting SSRI Response in Depression via miRNA and BDNF", 1], "107": ["SSRIs Effect on Reinforcement Learning in Rodents", 2], "108": ["Generic SSRIs", 1], "109": ["SSRIs for Dysthymia", 1], "110": ["Vilazodone for Depression", 1], "111": ["SSRIs for Trichotillomania", 1], "112": ["Selective serotonin reuptake inhibitors", 9], "113": ["SSRIs Long-term Efficacy and Recurrent Depression", 1], "114": ["SSRIs for the Mangement of Multiple Sclerosis", 1], "115": ["Neurochemical and Electrophysiological Correlates of SSRIs", 2], "116": ["Movement Disorders Associated with Fluvoxamine", 9], "117": ["Folate for Depression", 1], "118": ["SSRIs for Depression in Chronic Obstructive Pulmonary Disease (COPD) Patients", 1], "119": ["SSRIs Effect on Brain-derived Neurotrophic Factor (BDNF) Levels in Depressive Patients", 1], "120": ["Paroxetines Therapeutic Potential as G Protein-coupled Receptor Kinase 2 (GRK2) Inhibitor for Cardiovascular Diseases", 2], "121": ["SSRIs for Congenital Myasthenic Syndrome (SCCMS)", 1], "122": ["SSRIs for Depression in HIV-positive Patients", 1], "123": ["SSRIs in the Treatment of Huntington Disease", 1], "124": ["Loudness Dependence of Auditory Evoked Potentials (LDAEP) as Biomarker for Depression", 2], "125": ["SSRIs for Smoking Cessation", 1], "126": ["SSRIs for Syncope", 1], "127": ["Olfactory Bulbectomized (OB) Rat Model of Depression", 2], "128": ["Critical Psychiatry", 0], "129": ["Novel Compounds Synthesis and Antidepressant Potential", 2], "130": ["SSRIs for Tinnitus ", 1], "131": ["Tryptophan Depletion in Depression", 1], "132": ["Risk of Hallucinations", 1], "133": ["Exercise for Depression", 1], "134": ["SSRIs for Narcolepsy", 1], "135": ["SSRIs for Tourette's Syndrome", 1], "136": ["Adulterants of SSRIs in Weight Loss Supplements", 2], "137": ["Risk of Microscopic Colitis", 1], "138": ["Psilocybin for Depression", 1], "139": ["SSRIs for Psychotic Depression (STOP-PD Study)", 1], "140": ["SSRIs for OCD-like behaviors", 2], "141": ["SSRI Pharmacokinetics After Bariatric Surgery", 2], "142": ["Risk of Priapism", 1], "143": ["SSRIs for Depersonalization Disorder", 1], "144": ["Risk of Reversible Cerebral Vasoconstriction Syndrome (RCVS)", 1], "145": ["Pharmacokinetics and Brain Penetration Studies", 2], "146": ["SSRIs Cellular Distribution", 2], "147": ["Gateways to Clinical Trials", 9], "148": ["Citalopram Effects in Developing Mouse Brain", 2], "149": ["SSRIs for Olfactory reference syndrome (ORS)", 1]}